Open AccessPrimary prevention of chronic non-communicable diseases and acetylsalicylic acid: ambiguity of opinions
Author(s) -
В. Н. Ларина,
T. A. Gaydina,
Д. С. Мкртычев,
В. А. Кузнецова,
Zoya Snezhko
Publication year - 2020
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2020.3.n928
Subject(s) - medicine , diabetes mellitus , primary prevention , incidence (geometry) , intensive care medicine , disease , aspirin , optics , endocrinology , physics
Chronic noninfectious diseases (cardiovascular, bronchopulmonary, oncological diseases and diabetes mellitus) are presently the most common cause of death worldwide, with cardiovascular diseases (CVD) being predominant. For this reason, the key goal of a physician is not only to treat but also to prevent diseases. Acetylsalicylic acid (ASA) is considered one of the most effective drugs for secondary prevention of CVD. However, the use of ASA for primary prevention is still debated. Results of many studies of ASA are inconsistent. Some studies have suggested that using ASA in patients aged 40-70 with a high 10-year risk of CVD and a low risk of bleeding may reduce the incidence of CVD. Administration of ASA to patients with a high or medium risk of CVD is also considered.